Tuesday 1 July | 10:07:38 Europe / Stockholm

Subscription

Calendar

Est. time*
2025-11-13 08:00 Quarterly Report 2025-Q3
2025-08-21 08:00 Quarterly Report 2025-Q2
2025-05-07 - Ex-date Ordinary Dividend IMMU 0.00 SEK
2025-05-06 - Annual General meeting
2025-05-06 - Quarterly Report 2025-Q1
2025-02-13 - Year-end Report 2024
2024-11-08 - Quarterly Report 2024-Q3
2024-08-23 - Quarterly Report 2024-Q2
2024-06-03 - Split IMMU 20:1
2024-05-20 - Ex-date Ordinary Dividend IMMU 0.00 SEK
2024-05-17 - Annual General meeting
2024-05-17 - Quarterly Report 2024-Q1
2024-02-14 - Year-end Report 2023
2023-12-13 - Extra General Meeting 2023
2023-11-09 - Quarterly Report 2023-Q3
2023-08-29 - Quarterly Report 2023-Q2
2023-05-15 - Ex-date Ordinary Dividend IMMU 0.00 SEK
2023-05-12 - Annual General meeting
2023-05-12 - Quarterly Report 2023-Q1
2023-02-17 - Year-end Report 2022
2022-11-18 - Extra General Meeting 2022
2022-11-11 - Quarterly Report 2022-Q3
2022-08-26 - Quarterly Report 2022-Q2
2022-05-11 - Ex-date Ordinary Dividend IMMU 0.00 SEK
2022-05-10 - Annual General meeting
2022-05-10 - Quarterly Report 2022-Q1
2022-02-17 - Year-end Report 2021
2021-10-28 - Quarterly Report 2021-Q3
2021-08-26 - Quarterly Report 2021-Q2
2021-05-05 - Ex-date Ordinary Dividend IMMU 0.00 SEK
2021-05-04 - Annual General meeting
2021-05-04 - Quarterly Report 2021-Q1
2021-02-18 - Year-end Report 2020
2021-01-22 - Extra General Meeting 2021
2020-12-18 - Extra General Meeting 2020
2020-11-05 - Quarterly Report 2020-Q3
2020-08-27 - Quarterly Report 2020-Q2
2020-04-29 - Ex-date Ordinary Dividend IMMU 0.00 SEK
2020-04-28 - Annual General meeting
2020-04-28 - Quarterly Report 2020-Q1
2020-02-18 - Year-end Report 2019
2019-11-06 - Quarterly Report 2019-Q3
2019-08-20 - Quarterly Report 2019-Q2
2019-04-26 - Ex-date Ordinary Dividend IMMU 0.00 SEK
2019-04-25 - Annual General meeting
2019-04-25 - Quarterly Report 2019-Q1
2019-02-15 - Year-end Report 2018
2018-11-07 - Quarterly Report 2018-Q3
2018-08-17 - Quarterly Report 2018-Q2
2018-05-04 - Quarterly Report 2018-Q1
2018-04-26 - Ex-date Ordinary Dividend IMMU 0.00 SEK
2018-04-25 - Annual General meeting
2018-02-16 - Year-end Report 2017
2017-12-04 - Extra General Meeting 2017
2017-11-17 - Quarterly Report 2017-Q3
2017-08-18 - Quarterly Report 2017-Q2
2017-05-19 - Quarterly Report 2017-Q1
2017-04-27 - Ex-date Ordinary Dividend IMMU 0.00 SEK
2017-04-26 - Annual General meeting
2017-02-17 - Year-end Report 2016
2016-05-20 - Quarterly Report 2016-Q3
2016-02-19 - Quarterly Report 2016-Q2
2015-12-03 - Annual General meeting
2015-09-18 - Year-end Report 2015
2015-05-21 - Quarterly Report 2015-Q3
2015-02-20 - Quarterly Report 2015-Q2
2014-12-04 - Ex-date Ordinary Dividend IMMU 0.00 SEK
2014-12-03 - Annual General meeting
2014-11-18 - Quarterly Report 2015-Q1
2014-09-17 - Year-end Report 2014
2014-05-07 - Quarterly Report 2014-Q3
2014-02-18 - Quarterly Report 2014-Q2
2013-12-04 - Ex-date Ordinary Dividend IMMU 0.00 SEK
2013-12-03 - Annual General meeting
2013-12-03 - Quarterly Report 2014-Q1
2013-09-10 - Year-end Report 2013

Description

CountrySweden
ListSmall Cap Stockholm
SectorHealth care
IndustryBiotechnology
Mendus operates in the medical technology sector. The company produces therapeutic vaccines used in the field of oncology. The company researches new therapies that can improve patient outcomes and quality of life with a focus on the treatment of serious tumors. Examples of diseases that the products are used against include kidney and liver cancer. The largest operations are found in the Nordic market. Mendus was founded in 2002 and is headquartered in Stockholm, Sweden.
2025-02-21 08:00:00

Mendus AB ("Mendus" publ; IMMU. ST), ett biofarmabolag med fokus på immunterapier riktade mot tumöråterfall, meddelade idag att den första patienten har rekryterats till AMLM22-CADENCE-studien, som utvärderar Mendus ledande produkt vididencel som en ny underhållsbehandling av akut myeloisk leukemi (AML).

I denna randomiserade, multicenter, fas 2-studie utvärderar Australasian Leukaemia and Lymphoma Group (ALLG) vididencel som en ny underhållsbehandling av AML i kombination med oral azacitidin (AZA), för närvarande det enda godkända underhållsläkemedlet för AML. I studien får patienter med första fullständig remission efter intensiv induktionskemoterapi standardbehandling med AZA eller kombinationen AZA + vididencel. Vididencel administreras som 4 intradermala injektioner varannan vecka, följt av 3 boosterinjektioner upp till 6 månader efter behandlingens början.

I den första fasen av AMLM22-CADENCE-studien kommer 40 patienter att randomiseras, och i den andra fasen kommer effekten av kombinationen att bedömas hos ytterligare 100 patienter. Studien kommer att ge initiala säkerhetsdata för vididencel som tillägg till nuvarande standardbehandling och bidra till att ytterligare utöka den regulatoriska dokumentationen.